Thymosin-α1 in Cancer-Related Fatigue

Zhigang Zhang

Status and phase: Unknown; Phase 3

Conditions: Cancer Related Fatigue; Quality of Life

Treatments: Drug: Thymosin-α1

Study type: Interventional

Funder types: Other

Identifiers

NCT02127268

T-CRF

Details and patient eligibility

About

Cancer-related fatigue (CRF) is a distressing, persistent, subjective sense of physical, emotional, and/or cognitive tiredness or exhaustion related to cancer or cancer treatment that is not proportion to recent activity and interferes with usual functioning. Compared with general fatigue, CRF have the characteristics of long duration and generally cannot alleviate by rest or sleep, serious impact on the patient's work, study, entertainment and family life, and thus greatly affect the recovery, self-care ability and life quality of patients. Many dates showed that 70%~100% of cancer patients experienced cancer-related fatigue.For cancer-related fatigue there is no good treatment and intervention, in recent years, many clinical trials are carried out; central nervous stimulant, such as methylphenidate; acupuncture, aerobic exercise. All those measures may have certain therapeutic effect for CRF, but don't have exact evidences from massive RCT to confirm.

Thymosin-α1 (T-α1), a synthetic 28-amino acid peptide with multiple biological activities primarily directed towards immune response enhancement, this drug is used for the treatment of HBV and hepatitis C virus (HCV) infections, and being developed for the treatment of non-small cell lung cancer (NSCLC), hepatocellular carcinoma, AIDS and malignant melanoma. T-α1 is able to potentiate the action of cytokines and also reduce the hematological toxicity of cytotoxic drug therapy, such as cyclophosphamide, 5-fluorouracil, dacarbazine.

In this studies, we want to demonstrated that the effectiveness of Thymosin-α1 for cancer-related fatigue in cancer patients who undergo chemotherapy.

Enrollment: 200 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Men and women aged 18 years and older.
2. The life expectancy at least 6 months.
3. With a definite pathological diagnosis of cancer, and undergo chemotherapy.
4. Patients who are willing to participate in the study.

Exclusion criteria

1. Thymosin-α1 allergy.
2. Using the spirit excitement or stimulant drugs.
3. With brain metastasis or primary malignant brain tumors.
4. With mental disorders, such as suffering from dementia, delirium, obsessive-compulsive disorder, schizophrenia, epilepsy.
5. Other specific causes of fatigue: such as anemia, thyroid function is low, insomnia, uncontrolled pain.
6. Serious HRS cardiopulmonary function disorder.
7. Women during pregnancy and lactation.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

200 participants in 2 patient groups

Arm T

Active Comparator group

Description:

Will be treated with Thymosin-α1 1.6mg twice a week from day 1 of chemotherapy

Treatment:

Drug: Thymosin-α1

Arm B

No Intervention group

Description:

With best support according to NCCN Guideline